Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by equities researchers at Credit Suisse Group from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Sunday. The firm currently has a $23.00 price target on the stock. Credit Suisse Group’s target price points to a potential upside of 20.73% from the company’s previous close.
Other equities analysts also recently issued research reports about the stock. Leerink Swann dropped their price target on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating for the company in a research note on Friday. BTIG Research downgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating and set a $17.00 price target for the company. in a research note on Friday, February 2nd. Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday. Piper Jaffray Companies downgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and set a $11.00 price target for the company. in a research note on Friday. Finally, Cantor Fitzgerald set a $18.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. Ten research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the company. Teva Pharmaceutical Industries has an average rating of “Hold” and a consensus price target of $21.26.
Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.44 during trading hours on Friday, hitting $19.05. 1,649,645 shares of the company’s stock traded hands, compared to its average volume of 19,657,637. The firm has a market capitalization of $19,860.00, a P/E ratio of -1.17, a price-to-earnings-growth ratio of 1.37 and a beta of 0.59. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $37.94.
A number of institutional investors and hedge funds have recently made changes to their positions in TEVA. Calton & Associates Inc. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $108,000. Penserra Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries in the third quarter valued at $129,000. Fieldpoint Private Securities LLC purchased a new stake in Teva Pharmaceutical Industries in the third quarter valued at $171,000. Global Financial Private Capital LLC purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $193,000. Finally, Wetherby Asset Management Inc. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $197,000. 51.93% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Stock Rating Upgraded by Credit Suisse Group” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/11/teva-pharmaceutical-industries-teva-upgraded-to-outperform-at-credit-suisse-group.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.